Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
2 clusters · 4 sources · 4 days · First seen · Last updated
Sleep apnea research and diagnostic developments
Overview
Medical research and clinical observations regarding obstructive sleep apnea (OSA) have highlighted new treatment developments and risk factors. In the United States, the oral medication AD109 is under development to target muscle laxity in the oropharynx, showing a 44% reduction in the apnea-hypopnea index in early studies.
Clinical focus has also expanded to the hereditary and pediatric aspects of the condition. Research suggests that OSA is linked to a multifactorial hereditary component involving genetic variations and physical anatomy. In pediatric populations, where prevalence is estimated between 5% and 20%, experts warn that untreated apnea can lead to asthma, growth delays, irritability, and declining school performance. Early diagnosis remains a priority to mitigate long-term cardiovascular and developmental risks.
Entities
Mirian Valente · AD109 · Jessica Polese · Simone Prezotti · Santé respiratoire France
Timeline
-
[HEALTH] 2 sourcesSleep apnea risks and hereditary factors
Sleep apnea involves airway obstructions that can affect both adults and children. While influenced by genetics and anatomy, it is a multifactorial condition requiring early diagnosis to prevent long-term risks
-
[HEALTH] 2 sourcesSleep apnea treatments and pediatric warning signs identified
New research explores AD109, an oral medication for sleep apnea, while pediatricians warn that frequent snoring and behavioral changes in children may signal underlying sleep disorders.
Sources
fmm-mif.ca · handicap.fr · tribunaonline.com.br · vtvnews.com.br